CHOSA Oncology AB is at the forefront of a significant advancement in lung cancer treatment, utilizing its proprietary algorithm to predict patient responses to cisplatin. This development is particularly noteworthy given the widespread use of cisplatin and its sister molecule carboplatin in cancer therapies.

The study, conducted in collaboration with leading international experts, harnesses data from the SPLENDOUR trial, which involved over 500 patients. By applying its 205-gene test, CHOSA aims to identify which patients will benefit most from cisplatin, thereby optimizing treatment strategies and improving outcomes.

The significance of this study cannot be overstated. Cisplatin and carboplatin have been cornerstones in chemotherapy for decades, and the ability to predict their efficacy could revolutionize treatment protocols. CHOSA's algorithm, previously validated in breast cancer trials, holds promise for similar success in lung cancer.

Moreover, the study will explore the potential of the NanoString technology, which could expand CHOSA's capabilities and pave the way for future commercialization. This innovation is crucial as it aligns with the growing trend of personalized medicine, particularly in the lucrative PD-1/PD-L1 inhibitor market.

For investors, CHOSA's advancements present a compelling opportunity. The company's focus on precision medicine and its potential to enhance the efficacy of existing treatments make it a promising player in the oncology space. As the study progresses and more data becomes available, CHOSA's position in the market is likely to strengthen.

In light of these developments, the recommendation is to buy CHOSA Oncology shares. The company's innovative approach and strategic collaborations position it well for future growth and success in the oncology sector.